OBJECTIVE: Despite overwhelming biological plausibility, evidence for a protective effect of oestrogen on cognitive function in postmenopausal women is inconsistent. This study examines the association between endogenous oestrogen levels and subsequent 4-year decline in cognitive function test performance in community-dwelling older women. DESIGN: Longitudinal cohort study. PARTICIPANTS: Three hundred and forty-three postmenopausal women (median age 70 years). MEASUREMENTS: Between 1984 and 1987, serum for measurement of sex hormones was obtained along with relevant covariates. Cognitive function was assessed in 1988-1991 and again in 1992-1996 using the Category Fluency test, the Mini-Mental Status Exam (MMSE) and Trail Making Test B (Trails B). RESULTS: Women in the highest tertile of oestrone and bioavailable oestradiol had respectively 1.75 (95% CI 1.02, 3.07) and 1.79 (95% CI 1.04, 3.10) higher odds of 4 year decline in Category Fluency, a test of frontal lobe function, compared to those in the lowest tertile, independent of age and education. The 20% of women with highest tertile levels of both oestrone and bioavailable oestradiol had a twofold higher odds of verbal fluency loss (OR = 2.17; 95% CI 1.21, 3.89). Adjustment for testosterone levels or for obesity-related factors associated with high endogenous oestrogens (higher body mass index, waist girth, and triglycerides and lower high-density lipoprotein cholesterol) did not alter results. Neither oestrogen was associated with change in MMSE or Trails B scores. CONCLUSIONS: Higher endogenous oestrogen levels were associated with a greater decline in verbal fluency in postmenopausal women. This association was not explained by elevated androgens or by obesity or obesity-related factors.
OBJECTIVE: Despite overwhelming biological plausibility, evidence for a protective effect of oestrogen on cognitive function in postmenopausal women is inconsistent. This study examines the association between endogenous oestrogen levels and subsequent 4-year decline in cognitive function test performance in community-dwelling older women. DESIGN: Longitudinal cohort study. PARTICIPANTS: Three hundred and forty-three postmenopausal women (median age 70 years). MEASUREMENTS: Between 1984 and 1987, serum for measurement of sex hormones was obtained along with relevant covariates. Cognitive function was assessed in 1988-1991 and again in 1992-1996 using the Category Fluency test, the Mini-Mental Status Exam (MMSE) and Trail Making Test B (Trails B). RESULTS:Women in the highest tertile of oestrone and bioavailable oestradiol had respectively 1.75 (95% CI 1.02, 3.07) and 1.79 (95% CI 1.04, 3.10) higher odds of 4 year decline in Category Fluency, a test of frontal lobe function, compared to those in the lowest tertile, independent of age and education. The 20% of women with highest tertile levels of both oestrone and bioavailable oestradiol had a twofold higher odds of verbal fluency loss (OR = 2.17; 95% CI 1.21, 3.89). Adjustment for testosterone levels or for obesity-related factors associated with high endogenous oestrogens (higher body mass index, waist girth, and triglycerides and lower high-density lipoprotein cholesterol) did not alter results. Neither oestrogen was associated with change in MMSE or Trails B scores. CONCLUSIONS: Higher endogenous oestrogen levels were associated with a greater decline in verbal fluency in postmenopausal women. This association was not explained by elevated androgens or by obesity or obesity-related factors.
Authors: Kristine Yaffe; Eric Vittinghoff; Kristine E Ensrud; Karen C Johnson; Susan Diem; Vladimir Hanes; Deborah Grady Journal: Arch Neurol Date: 2006-07
Authors: Susan M Resnick; Laura H Coker; Pauline M Maki; Stephen R Rapp; Mark A Espeland; Sally A Shumaker Journal: Clin Trials Date: 2004 Impact factor: 2.486
Authors: Joanna L Spencer; Elizabeth M Waters; Russell D Romeo; Gwendolyn E Wood; Teresa A Milner; Bruce S McEwen Journal: Front Neuroendocrinol Date: 2007-10-15 Impact factor: 8.606
Authors: Mark A Espeland; Robert L Brunner; Patricia E Hogan; Stephen R Rapp; Laura H Coker; Claudine Legault; Iris Granek; Susan M Resnick Journal: J Am Geriatr Soc Date: 2010-07 Impact factor: 5.562
Authors: Hubert W Vesper; Julianne C Botelho; Meghan L Vidal; Yasamin Rahmani; Linda M Thienpont; Samuel P Caudill Journal: Steroids Date: 2014-01-06 Impact factor: 2.668
Authors: E Candeias; A I Duarte; I Sebastião; M A Fernandes; A I Plácido; C Carvalho; S Correia; R X Santos; R Seiça; M S Santos; C R Oliveira; P I Moreira Journal: Mol Neurobiol Date: 2016-10-11 Impact factor: 5.590
Authors: Alison Berent-Spillson; Carol C Persad; Tiffany Love; MaryFran Sowers; John F Randolph; Jon-Kar Zubieta; Yolanda R Smith Journal: J Clin Endocrinol Metab Date: 2012-06-22 Impact factor: 5.958
Authors: Mark A Espeland; Sally A Shumaker; Iris Leng; JoAnn E Manson; Candice M Brown; Erin S LeBlanc; Leslie Vaughan; Jennifer Robinson; Stephen R Rapp; Joseph S Goveas; Jean Wactawski-Wende; Marcia L Stefanick; Wenjun Li; Susan M Resnick Journal: JAMA Intern Med Date: 2013-08-12 Impact factor: 21.873
Authors: M Maggio; E Dall'Aglio; F Lauretani; C Cattabiani; G Ceresini; P Caffarra; G Valenti; R Volpi; A Vignali; G Schiavi; G P Ceda Journal: J Nutr Health Aging Date: 2012-01 Impact factor: 4.075
Authors: Alain K Koyama; Shelley S Tworoger; A Heather Eliassen; Olivia I Okereke; Marc G Weisskopf; Bernard Rosner; Kristine Yaffe; Francine Grodstein Journal: Alzheimers Dement Date: 2016-01-21 Impact factor: 21.566
Authors: William Rosner; Susan E Hankinson; Patrick M Sluss; Hubert W Vesper; Margaret E Wierman Journal: J Clin Endocrinol Metab Date: 2013-03-05 Impact factor: 5.958